Literature DB >> 10665703

Arterial hypertension and renal allograft survival.

K C Mange1, B Cizman, M Joffe, H I Feldman.   

Abstract

CONTEXT: Several observational studies have investigated the significance of hypertension in renal allograft failure; however, these studies have been complicated by the lack of adjustment for baseline renal function, leaving the role of elevated blood pressure in allograft failure unclear.
OBJECTIVE: To examine the relationship between blood pressure adjusted for renal function and survival after cadaveric allograft transplantation.
DESIGN: Nonconcurrent historical cohort study conducted from 1985 through 1997.
SETTING: University teaching hospital. PARTICIPANTS: A total of 277 patients aged 18 years or older who underwent cadaveric renal transplantation without another simultaneous organ transplantation and whose allograft was functioning for a minimum of 1 year. Follow-up continued through 1997 (mean follow-up, 5.7 years). MAIN OUTCOME MEASURE: Time to allograft failure (defined as death, return to dialysis, or retransplantation) by systolic, diastolic, and mean arterial blood pressure measurements at 1 year after transplantation.
RESULTS: Multivariate Cox proportional hazards modeling demonstrated that nonwhite ethnicity, history of acute rejection, and nondiabetic kidney disease were significant predictors of failure (P = .01 for all). In addition, the calculated creatinine clearance at 1 year had an adjusted rate ratio (RR) for allograft failure per 10 mL/min (0.17 mL/s) of 0.74 (95% confidence interval [CI], 0.62-0.88). The RR per 10-mm Hg increase in blood pressure measured at 1 year after transplantation, after adjustment for creatinine clearance, was 1.15 (95% CI, 1.02-1.30) for systolic pressure, 1.27 (95% CI, 1.01-1.60) for diastolic pressure, and 1.30 (95% CI, 1.05-1.61) for mean arterial pressure. Supplemental analyses that did not include death as a failure event or reduce the minimum allograft survival time for study subjects to 6 months yielded results consistent with the primary analysis. There was no evidence of modification of the blood pressure-allograft failure relationship by ethnicity or diabetes mellitus.
CONCLUSIONS: Systolic, diastolic, and mean arterial blood pressures at 1 year posttransplantation strongly predict allograft survival adjusted for baseline renal function. More aggressive control of blood pressure may prolong cadaveric allograft survival.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10665703     DOI: 10.1001/jama.283.5.633

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  57 in total

1.  FK506 binding protein 12 deficiency in endothelial and hematopoietic cells decreases regulatory T cells and causes hypertension.

Authors:  Valorie L Chiasson; Deepa Talreja; Kristina J Young; Piyali Chatterjee; Amy K Banes-Berceli; Brett M Mitchell
Journal:  Hypertension       Date:  2011-04-25       Impact factor: 10.190

2.  Tacrolimus-induced hypertension: what's endothelial and hematopoietic FKBP12 got to do with it?

Authors:  Sean P Didion
Journal:  Hypertension       Date:  2011-04-25       Impact factor: 10.190

Review 3.  Cardiovascular risk factors following renal transplant.

Authors:  Jill Neale; Alice C Smith
Journal:  World J Transplant       Date:  2015-12-24

Review 4.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

5.  Trans-forming endothelial nitric oxide synthase in hypertension: more than meets the eye.

Authors:  Andrew W Johnson; Frank M Faraci
Journal:  Hypertension       Date:  2011-08-01       Impact factor: 10.190

6.  Pin1 deficiency causes endothelial dysfunction and hypertension.

Authors:  Valorie L Chiasson; Nidhi Munshi; Piyali Chatterjee; Kristina J Young; Brett M Mitchell
Journal:  Hypertension       Date:  2011-08-01       Impact factor: 10.190

Review 7.  How aggressively should blood pressure be treated in renal transplant recipients?

Authors:  D K Klassen
Journal:  Curr Hypertens Rep       Date:  2000-10       Impact factor: 5.369

Review 8.  Post-transplant diabetes mellitus: risk reduction strategies in the elderly.

Authors:  Alain Duclos; Lawrence M Flechner; Charles Faiman; Stuart M Flechner
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

9.  Tacrolimus reduces nitric oxide synthase function by binding to FKBP rather than by its calcineurin effect.

Authors:  Leslie G Cook; Valorie L Chiasson; Cheng Long; Gang-Yi Wu; Brett M Mitchell
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

10.  ACE inhibition in the treatment of children after renal transplantation.

Authors:  Klaus Arbeiter; Andrea Pichler; Regina Stemberger; Thomas Mueller; Dagmar Ruffingshofer; Regina Vargha; Egon Balzar; Christoph Aufricht
Journal:  Pediatr Nephrol       Date:  2003-12-13       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.